Tafsure (Tenofovir Alafenamide)
Description of Tafsure 25mg (Tenofovir Alafenamide 25mg)
Tafsure 25mg (Tenofovir Alafenamide 25mg) is an anti-hepaciviral & anti-retroviral medicine. In HIV infected patients, Tafsure 25mg (Tenofovir Alafenamide 25mg) is not used alone and it may combine with some other anti-retroviral medicines like Emtricitabine, cobicistat, or darunavir. At first, Tafsure 25mg (Tenofovir Alafenamide 25mg) is belongs to anti-retroviral (nucleoside reverse transcriptase inhibitor), now Tafsure 25mg (Tenofovir Alafenamide 25mg) has anti-hepaciviral property which is used against hepatitis B viral infection
Medical use /Indication of Tafsure 25mg (Tenofovir Alafenamide 25mg)
Prior usage of Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet, used in HIV-1 infection Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet is also indicated for the treatment of hepatitis B viral infection, by reducing the advancement of virus Tafsure 25mg (Tenofovir Alafenamide 25mg) used in chronic hepatitis B infection, is non-curable but it can able to prevent the viral transmission
CATEGORY:
Anti-retroviral medicine
Anti-hepaciviral medicine
Works as of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Tafsure 25mg (Tenofovir Alafenamide 25mg)-Tenofovir Alafenamide (TAF) TAF is a promedicine of tenofovir (parent medicines) At first, TAF is penetrating into hepatic cells because it has lipophilic cell permeable capacity. After enters into the cells, TAF undergoes hydrolysis by using carboxylesterase-1 and to formed as tenofovir. Tenofovir involved in intracellular metabolism, which is phosphorylated into tenofovir triphosphate. Tenofovir triphosphate is considered as an active metabolite which has anti-viral property and integrated into viral DNA by hepatitis B reverse transcriptase enzyme and leads to inhibits viral production thus results as termination of viral chain.
How the body works for Tafsure 25mg (Tenofovir Alafenamide 25mg) tablets
After an oral administration, absorption of Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet occurs rapidly. The peak plasma time occurs within 0.48 hours The effect of food while taking Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet is includes as; With high fat meal, the effect of Tenofovir Alafenamide is 1.65 Tafsure 25mg (Tenofovir Alafenamide 25mg) is highly bound to human plasma protein nearly 80% The blood plasma ration is 1.0 Metabolism of Tenofovir Alafenamide is occurs with the aid of cathepsin A, carboxylesterase-1 The half life period of Tenofovir Alafenamide is 0.51 hour Excretion occurs through urine <1%; feces 31.7%
Side effects of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Important adverse effects;
Lactic acidosis or severe hepatomegaly with steatosis
Reactivation of hepatitis B viral infection in worsening condition after the therapy
Renal damage occurs
Some of undesirable effects;
Headache
Fatigue
Cough
Nausea
Back pain
Abdominal pain
Reduction in bone mineral density
Glycosuria
Creatine kinase elevation
Amylase lipase elevated.
Precaution of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
- After cessation of anti-hepatitis B therapy by using with Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet, concluded in serious intense aggravation of hepatitis B infection. To avoid this adverse condition in the patients, liver function should be observed frequently.
- Exposure of reinforcement of HIV-1 antagonism in HBV/HIV-1 co infected patients In HIV infected patients, combinational therapy is suggested for avoiding this condition in co-infected patients. Check the HIV antibody in all HBV infected patients before starting the therapy.
- New commencement and worsening of renal damage Patient with low renal function capability, stop the Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet therapy immediately and monitored the serum phosphorus, serum creatinine, urine protein, urine glucose and creatinine clearance frequently
- Lactic acidosis or serious hepatomegaly with steatosis If this condition occurred in the patients, immediately discontinue the therapy and provide safety measures
Drug interaction of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Tafsure 25mg (Tenofovir Alafenamide 25mg) combined with P-gp or BCRP strong inhibitors, results as alteration of absorption of Tenofovir Alafenamide P-gp or BCRP inducers, combined with Tafsure 25mg (Tenofovir Alafenamide 25mg) tablets leads to cause loss of therapeutic effect of Tafsure 25mg (Tenofovir Alafenamide 25mg). Tafsure 25mg (Tenofovir Alafenamide 25mg) with P-gp or BCRP moderate inhibitors results as absorption elevation thus causes plasma concentration of Tenofovir Alafenamide. Tafsure 25mg (Tenofovir Alafenamide 25mg) tablets combined with anti-convulsants (phenytoin, carbamazepine, or Phenobarbital), anti-mycobacterials (rifampin, rifapentine, or rifabutin) or herbal products (st Johns wort) causes depletion in effect of concentration of Tafsure 25mg (Tenofovir Alafenamide 25mg).
Over dosage of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
In over dosage condition, two steps follows :
1. Examine the deposition of toxicity and symptoms occurred due to over dosage
2. Hemodialysis, a method involved in eradicating the over dosage of Tafsure 25mg (Tenofovir Alafenamide 25mg) with separation coefficient of 54%
Pregnancy & Lactation of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Tafsure 25mg (Tenofovir Alafenamide 25mg) is rational use, in some patients placental transformation happens
In breast feeding and lactation condition, Tafsure 25mg (Tenofovir Alafenamide 25mg) is used only under the guidance of medical practitioner.
Dosage of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
The usual dosage of Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet is, one tablet containing 25mg of Tenofovir Alafenamide should be taken as a single dose Tafsure 25mg (Tenofovir Alafenamide 25mg) tablet should be administered with food In creatinine clearance range <15ml/min, Tafsure 25mg (Tenofovir Alafenamide 25mg) is not recommended In decompensated cirrhosis: Tafsure 25mg (Tenofovir Alafenamide 25mg) should not be recommended Before initiating the therapy: Patients should examine HIV-1 infection for recommending combination of other anti-retroviral medicines in HIV-1 positive patients.
Storage of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Tafsure 25mg (Tenofovir Alafenamide 25mg) tablets container is stored under room temperature below 30 ℃. Tafsure 25mg (Tenofovir Alafenamide 25mg) container should be kept in dry and cool place and should be free from heat, moisture Protect from light
Missed dose of Tenfoplus 25mg (Tenofovir Alafenamide 25mg)
Once missed dose occurred, patient must consult with medical practitioner and follow the instruction. On another way, missed dose should be skipped and proceed from regular dosing schedule.
No reviews found